BMC: 肠粘膜中IL-12表达增加与溃疡性结肠炎的复发有关

2021-03-24 MedSci原创 MedSci原创

炎症性肠病(IBD)是包括溃疡性结肠炎(UC)和克罗恩氏病(CD)的一种慢性病,其特征是肠道反复出现炎症。

      炎症性肠病(IBD)是包括溃疡性结肠炎(UC)和克罗恩氏病(CD)的一种慢性病,其特征是肠道反复出现炎症。免疫细胞(如T辅助细胞)和细胞因子(如白介素)都参与了疾病的发病。由于炎症介质与IBD的发病机理有关,因此这些分子已被用作其治疗的治疗靶标。TNF-α是第一个被确定为控制IBD的治疗靶标的分子,许多TNF-α抑制剂已被临床批准用于CD和UC的治疗。目前,另外一个细胞因子IL-12的促炎作用得到了越来越多的重视,IL-12首先被鉴定为促进干扰素(IFN)-γ产生的天然杀伤细胞刺激因子(NKSF)。有报道说,接受结直肠手术的UC患者发炎的黏膜中IL-12 mRNA表达显着升高,在本研究中,研究人员调查了粘膜IL-12表达与UC患者临床结局之间的关联。

 

 

      研究人员从70例临床缓解的UC患者中收集直肠活检。通过实时荧光定量PCR测量IL-12,IL-23,IFN-γ,IL-17A和IL-17F mRNA的表达。内窥镜检查的严重程度和组织学活性分别通过Mayo内窥镜评分(MES)和Geboes评分进行评估。

 

 

 

      本项研究中最长的随访期为51个月,在研究期间有34名患者复发。这些后来复发的患者的样品组成“复发”组,而那些未复发的患者的样品组成“缓解”组。 复发组中IL-12(P  = 0.0003)和IL-23(P = 0.014)mRNA表达显着高于缓解组。IL-23(P  = 0.015)而不是IL-12(P  = 0.374)的表达与MES评分相关。但是,在MES为0和1的患者中,IL-12在复发中的表达在统计学上高于缓解组(P  = 0.0015,P = 0.0342)。但是在缓解组中无组织学活动的患者两者均较高(IL-12:P=0.0002,IL-23:P  = 0.046)。

 

 

   

      本项研究发现在复发的UC患者中,患者的直肠粘膜中IL-12和IL-23表达均升高,但是无论内窥镜检查的严重程度和组织学活性如何,IL-12与UC复发的相关性更高。因此,研究人员说道IL-12在UC发病与复发中有着重要的作用。

 

 

 

原始出处:

Kazuhiko Uchiyama. Et al. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterology.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695227, encodeId=0c02169522eb4, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Sep 02 02:33:12 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9627, encryptionId=ef8e962eb5, topicName=IL-12)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 17 13:33:12 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975063, encodeId=f7c919e506325, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 13 16:33:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691088, encodeId=2dff16910886e, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Apr 11 11:33:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508306, encodeId=8e7915083060b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Mar 26 01:33:12 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-09-02 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695227, encodeId=0c02169522eb4, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Sep 02 02:33:12 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9627, encryptionId=ef8e962eb5, topicName=IL-12)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 17 13:33:12 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975063, encodeId=f7c919e506325, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 13 16:33:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691088, encodeId=2dff16910886e, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Apr 11 11:33:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508306, encodeId=8e7915083060b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Mar 26 01:33:12 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695227, encodeId=0c02169522eb4, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Sep 02 02:33:12 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9627, encryptionId=ef8e962eb5, topicName=IL-12)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 17 13:33:12 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975063, encodeId=f7c919e506325, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 13 16:33:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691088, encodeId=2dff16910886e, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Apr 11 11:33:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508306, encodeId=8e7915083060b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Mar 26 01:33:12 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695227, encodeId=0c02169522eb4, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Sep 02 02:33:12 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9627, encryptionId=ef8e962eb5, topicName=IL-12)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 17 13:33:12 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975063, encodeId=f7c919e506325, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 13 16:33:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691088, encodeId=2dff16910886e, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Apr 11 11:33:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508306, encodeId=8e7915083060b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Mar 26 01:33:12 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-04-11 guoyibin
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695227, encodeId=0c02169522eb4, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Sep 02 02:33:12 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9627, encryptionId=ef8e962eb5, topicName=IL-12)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 17 13:33:12 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975063, encodeId=f7c919e506325, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 13 16:33:12 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691088, encodeId=2dff16910886e, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Apr 11 11:33:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508306, encodeId=8e7915083060b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Mar 26 01:33:12 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-03-26 jjjiang0202

相关资讯

Mirikizumab达到溃疡性结肠炎研究的主要终点

溃疡性结肠炎(UC)是大肠的一种慢性疾病,常常使人衰弱,并影响全球数百万人。UC的症状可能包括血液和粘液引起的慢性腹泻、腹痛和绞痛以及体重减轻。UC可以对工作、家庭和社交活动产生重大影响。

英夫利昔单抗对难治性溃疡性结肠炎的疗效“更佳”

圣迭戈(EGMN)——在医院医学会年会上,加州大学圣迭戈分校的胃肠病学家Derek R. Patel博士指出,英夫利昔单抗是重度急性激素难治性溃疡性结肠炎(UC)的最佳补救治疗。   在一项随机研究中,Laharie博士及其同事比较了56例接受英夫利昔单抗治疗的激素难治性UC患者和55例接受环孢菌素治疗的相似患者,结果显示各组1周内的有效率均约为85%。随访第3个月时,环孢菌素组和英